Can whole-genome sequencing (WGS) compete with targeted sequencing approaches? The debate ratcheted up a notch when on June 5 next-generation WGS service provider Complete Genomics Inc. tabled its plan to double capacity to 2,000 genomes per month by the end of the third quarter this year. Until, it said, “demand for clinical-grade genomes supports expansion.” Then, two days later, Foundation Medicine Inc. (FMI) announced a new agreement with Novartis AG under which the pharma will deploy FMI’s next-gen sequencing-based molecular tumor profiling platform across many of its early-stage oncology programs.
Both firms market their platforms to pharma for use in clinical drug development, and both have been eying the clinical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?